The phase 1b, 16-week, multiple-dose ascending trial (NCT05613387) showed a mean body weight reduction of 4.8%, 8.6% and 8.3% at OW doses of up to 2.4 mg, 4.8 mg and 9.0 mg, respectively [116]
Severe or persistent gastrointestinal side effectsincluding intractable nausea, vomiting, or diarrhoea leading to dehydrationmay necessitate stopping the medication
10.3389/fphar.2020.00264 41 FanY.ChenH.PengH.HuangF.ZhongJ.ZhouJ
While cobalamin overdose is unheard of because it is non-toxic and water-soluble, cobalamin deficiency can happen due to a number of reasons, including certain diseases and genetic defects.
In contrast, semaglutide selectively activates the GLP-1 receptor, while retatrutide engages three related receptors across the incretin hormone family
The relative risk was therefore around five times higher